Post acquisition Phadia will become a part of Thermo Fisher’s Specialty Diagnostics business.

Thermo Fisher president and CEO Marc Casper said the acquisition of Phadia enhances their presence in specialty diagnostics markets by adding allergy and autoimmunity diagnostic tests.

"We are delighted to welcome Phadia’s employees to our team and look forward to work together to expand our depth of capabilities for our customers who are focused on improving healthcare through better diagnostics," Casper said.